Long-term comparative analysis from an all-comer cohort of coronary patients treated using first-and second-generation drug-eluting stents

Journal of Invasive Cardiology

Volumn 26, Issue 8, 2014, Pages 378-384

  Codner, Pablo ^a   Bental, Tamir ^a   Assali, Abid ^a   Vaknin Assa, Hana ^a   Lev, Eli ^a   Kornowski, Ran ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

bare metal stent; drug eluting stent; sirolimus eluting stent

Indexed keywords

'TAXUS'; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; REVASCULARIZATION; ADVERSE DRUG REACTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLASSIFICATION; COMPARATIVE EFFECTIVENESS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEVICES; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROGNOSIS; PROSTHESIS DESIGN; TIME FACTOR; TREATMENT OUTCOME;

AGED; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905436024     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363(24):2310-2319.
2. Mauri L, Massaro JM, Jiang S, et al. Long term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv. 2010;3(12):1240-1249.
3. Lagerqvist B, James SK, Stenestrand U, et al. SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009-1019.
4. Bangalore S, Kumar S, Fusaro M, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-2891.
5. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52(1):249-264.
6. Cabral MD, Luiz RR. Sensitivity analysis for unmeasured confounders using an electronic spreadsheet. Rev Saude Publica. 2007;41(3):446-452.
7. Bental T, Assali A, Vaknin-Assa H, et al. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare-metal stents in a large consecutive patient cohort. Catheter Cardiovasc Interv. 2010;76(3):374-380.
8. Kornowski R, Vaknin-Assa H, Assali A, et al. A comparative analysis of major clinical outcomes with drug-eluting stents versus bare metal stents in male versus female patients. EuroIntervention. 2012;7(9):1051-1059.
9. Minha S, Bental T, Assali A, et al. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients. Catheter Cardiovasc Interv. 2011;78(5):710-717.
10. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008;118(18):1817-1827.
11. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254-265.
12. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123(13):1400-1409.
13. Onuma Y, Miquel-Hebert K, Serruys PW; SPIRIT II Investigators. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention. 2013;8(9):1047-1051.
14. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375(9710):201-209.
15. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of everolimus-and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials. JACC Cardiovasc Interv. 2011;4(10):1104-1115.
16. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606-613.
17. Rasmussen K, Maeng M, Kaltoft A, et al; SORT OUT III Study Group. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010;375(9720):1090-1099.
18. Jensen LO, Thayssen P, Hansen HS, et al; Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125(10):1246-1255.
19. Jensen LO, Thayssen P, Christiansen EH, et al; SORT OUT IV Investigators. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) trial. J Am Coll Cardiol. 2012;60(13):1140-1147.
20. Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012;5(3):357-364.